

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
<p>The public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing the collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing the burden, to the Department of Defense, Executive Service Directorate (0704-0188). Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number.</p> <p>PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ORGANIZATION.</p>					
1. REPORT DATE (DD-MM-YYYY) 08/27/2017		2. REPORT TYPE Poster		3. DATES COVERED (From - To) 08/27/2017-08/30/2017	
4. TITLE AND SUBTITLE Investigation of intravenous hydroxocobalamin compared to Hextend for resuscitation in a swine model of uncontrolled hemorrhagic shock: A preliminary report				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER	
				5c. PROGRAM ELEMENT NUMBER	
				5d. PROJECT NUMBER	
6. AUTHOR(S) Maj Joseph Maddry				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBSA-Lackland, TX 78236-9908 210-292-7141				8. PERFORMING ORGANIZATION REPORT NUMBER 17359	
9. SPONSORING/MONITORING AGENCY NAME(S) AND ADDRESS(ES) 59th Clinical Research Division 1100 Willford Hall Loop, Bldg 4430 JBSA-Lackland, TX 78236-9908 210-292-7141				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION/AVAILABILITY STATEMENT Approved for public release. Distribution is unlimited.					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT					
15. SUBJECT TERMS					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			Clarice Longoria
					19b. TELEPHONE NUMBER (Include area code) 210-292-7141

Investigation of intravenous Hydroxocobalamin compared to Hextend® for resuscitation in a swine model of uncontrolled hemorrhagic shock: a preliminary report

JK Maddry^{1,4}, VS Bebart², D Hyams¹, N Garrett³, S Boudreau⁴, M Castaneda⁴, K Canellis⁴

¹Dept of Emergency Medicine, San Antonio Military Medical Center, San Antonio, TX, ²University of Colorado-Denver, ³Geneva Foundation, San Antonio, TX, ⁴Clinical Resuscitation, Emergency Sciences, and Toxicology Research Program Program, Wilford Hall Ambulatory Surgical Center, Lackland AFB, TX,



Background

Previously we reported that intravenous (IV) hydroxocobalamin is as effective as IV Hextend® in improving systolic blood pressure (SBP) in a controlled hemorrhagic shock model. We aimed to compare IV hydroxocobalamin (HOC) to Hextend® using an uncontrolled hemorrhage model. Non-compressible wounds are difficult to treat. An ideal resuscitative fluid would be a small volume, portable drug that improves blood pressure and survival.


Objective

To compare systolic blood pressure over time in swine that have undergone hemorrhagic shock induced by lethal groin injury.

Methods

Experiment: 12 swine, 45-55kg were anesthetized, intubated, and instrumented with continuous femoral and pulmonary artery pressure monitoring. A groin injury was created by surgically exposing and transecting a femoral artery and vein. A suction catheter connected a canister placed distal to the wound measured blood loss. Swine were bled to a SBP of 40 mmHg then packed with QuikClot followed by 5 minutes of manual pressure. A chest seal was then applied. Animals were randomized to receive 150 mg/kg IV HOC, or 500 mL of Hextend® and monitored for 120 minutes.

Methods cont.




Statistics: A sample size of 9 animals per group was determined based on a power of 80% and an alpha of 0.05 to detect an effect size of at least 0.25 difference (1SD) in SBP between groups. Data were analyzed using repeated measures MANOVA. Data collection is ongoing.

Results


There were no significant differences between the HOC or Hextend groups at baseline or at shock (SBP 52 vs. 59 mmHg), nor was there a significant difference in blood loss from the injury (1005 vs 1100 mL). There was a significant difference by time between groups ($p < 0.5$) post treatment. No significant difference in SBP, MAP or HR between groups. SVR was significantly higher and CO significantly lower in the HOC compared to Hextend® treated animals.

Graph 1. SBP for IV HOC vs. IV Hextend®




Results Continued

Graph 2. SVR for IV HOC vs. IV Hextend®



Graph 3. CO for IV HOC vs. IV Hextend®



Limitations

Animal model
Not blinded

Conclusions

IV HOC was as effective as Hextend® in supporting SBP in an uncontrolled hemorrhagic shock model. HOC resulted in an statistically significant increase in SVR and decrease in CO.